Industry & Policy News

[Evexta Bio SA] Evexta Bio SA provided an update on the clinical development of its lead asset, rupitasertib, a selective oral inhibitor of S6K and AKT1/AKT3.

[Palisade Bio, Inc.] Palisade Bio, Inc. announced the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by ulcerative colitis.

[Insider Precision Medicine] Researchers at the University of California, San Francisco (UCSF) have begun enrollment for a clinical trial that uses a new, powerful version of CAR T as a potential therapy for glioblastoma, the most common and deadly adult brain cancer.

[University of Toronto] The University of Toronto (U of T) is collaborating with the University Health Network, the Hospital for Sick Children, and Sunnybrook Research Institute on a new program that aims to leverage the expertise of entrepreneurs and business leaders to advance commercialization of emerging medical technologies and regenerative medicine research.

[Business Insider] Healthcare innovator Dr. David Greene announced the establishment of the esteemed Dr. David Greene Scholarship for Medical Students, aimed at fostering excellence and innovation in the medical community. This scholarship, valued at $1,000, presents a unique chance for undergraduate students to further their medical ambitions.

[Hubrecht Institute] Delilah Hendriks, researcher from the Organoid group, Oncode researcher, and affiliated group leader at the Princess Máxima Center has received a Young Investigator Grant from the Dutch Cancer Society.